Acquisition History StelKast was acquired by Globus Medical for $24.1M and assets sold in 2019, indicating a historical shift in ownership and potential integration opportunities, legacy product lines, and ongoing influence in orthopedic instrumentation through the acquirer.

Midmarket Focus Current revenue range of 1–10 million with 11–50 employees places StelKast in the midmarket segment, suggesting a buyer profile that values scalable partnerships, streamlined procurement, and targeted OEM collaborations for implant instruments.

Orthopedic Expertise Deep metallurgical and manufacturing engineering leadership, plus a full line of knee and hip implants developed with clinician input, positions StelKast as a potential partner for advanced components, tooling, and instrument sets requiring high precision and regulatory alignment.

Technological Footprint Tech stack includes modern web analytics and security tools (Google Analytics, Google Conversion Tracking, Mimecast), as well as Drupal-based site infrastructure, indicating a mature digital presence suitable for partner-facing platforms, catalogs, and digital procurement integrations.

Growth Signals Past acquisition activity by Globus Medical and a clearly defined product focus on implants suggests opportunities to pursue collaboration on new product lines, instrument design enhancements, or strategic distribution arrangements within orthopedic markets and replacement segments.